Quantum Leap Healthcare Collaborative

Latest Updates

Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
I-SPY Email List Sign-up

 Press Releases

View All
Quantum Leap Healthcare Collaborative Announces AstraZeneca's Olaparib And Durvalumab‎ For The I-SPY 2 Trial For Breast Cancer

A combination of poly (ADP-ribose) polymerase (PARP) enzyme inhibitor olaparib and anti-PD-L1 monoclonal antibody immunotherapy agent durvalumab, both from AstraZeneca, will be evaluated in I-SPY 2.

September 6, 2018

Long-term efficacy results from the I-SPY 2 TRIAL indicate pathological complete response (pCR) is a powerful predictor for breast cancer survival

Data Presented at San Antonio Breast Cancer Symposium Show Significant and Clinically Impactful Relationship Between pCR and Event-Free Survival in High-Risk Breast Cancer.

December 7, 2017


View All

September 14, 2018

Advanced MRI methods tested in I-SPY 2 may improve monitoring and prediction of treatment response

I-SPY investigators lauded for ‘mammoth task’ of imaging quality control in multicenter trials

September 7, 2018

I-SPY 2 TRIAL featuring three abstracts at ASCO's 2018 Annual Meeting

Three results from I-SPY’s adaptive trial design being showcased at ASCO 2018.

May 30, 2018

 In the News

View All